CM-3: Phase I start

Next month, Biocompatibles' CellMed unit will begin a Phase I trial. AstraZeneca plc (LSE:AZN; NYSE:AZN, London, U.K.) has an exclusive option to license CM-3 (see BioCentury, Jan. 5). ...